Protective immunity against SARS-CoV-2 in immunosuppressed COVID-19 convalescents after liver transplantation

Project leader: Dr. med. Richard Taubert

Key area

  • Pathophysiology: immunomodulation and immune control

Who is involved?

  • Dr. med. Richard Taubert (Project leader, MHH)
  • Prof. Dr. Yang Li (CiiM, HZI)

What is the aim?

Do immunosuppressed patients after COVID-19 disease develop an immune response as good as non-immunosuppressed convalescents? Methods: Measurement of the immune response directed against SARS-CoV-2 (antibodies IgG/A/M and interferon release) in the blood of immunosuppressed patients after liver transplantation and autoimmune hepatitis longitudinal within the first year after COVID-19 disease in comparison to non-immunosuppressed patients.

Which COFONI technology platform is involved?


  • SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis. Theresa Kirchner, Elmar Jaeckel, Christine S. Falk, Britta Eiz-Vesper, Richard Taubert. Journal of Hepatology, Volume 75, Issue 6, 2021,
  • Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplantation recipients in the first year after COVID-19. Theresa Kirchner, Sophia Heinrich, Agnes Bonifacius, Bastian Engel, Louisa Ruhl, Isabell Pink, Nele Thomas, Jörg Martens, Marius M Hoeper, Rainer Blasczyk, Heiner Wedemeyer, Elmar Jaeckel, Christine S. Falk, Britta Eiz-Vesper, Richard Taubert. Journal: PLoS ONE 2022: 17(11): e0276929. doi: 10.1371/journal.pone.0276929

Follow us